NCT07710885
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07710885
Title Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer (FOENIX-BTC)
Acronym FOENIX-BTC
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Taiho Pharmaceutical Co., Ltd.
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS

Facility Status City State Zip Country Details
Research Site NOT_YET_RECRUITING Brisbane Australia Details
Research Site NOT_YET_RECRUITING Melbourne Australia Details
Research Site NOT_YET_RECRUITING Perth Australia Details
Research Site NOT_YET_RECRUITING Sydney Australia Details
Research Site NOT_YET_RECRUITING Aichi Japan Details
National Hospital Organization Kyushu Cancer Center RECRUITING Fukuoka Japan Details
Research Site NOT_YET_RECRUITING Fukuoka Japan Details
Research Site NOT_YET_RECRUITING Hokkaido Japan Details
Kanagawa Cancer Center NOT_YET_RECRUITING Kanagawa Japan Details
Research Site NOT_YET_RECRUITING Miyagi Japan Details
Research Site NOT_YET_RECRUITING Osaka Japan Details
Research Site NOT_YET_RECRUITING Tokyo Japan Details
The Cancer Institute Hospital RECRUITING Tokyo Japan Details
Toyama University Hopspital RECRUITING Toyama Japan Details
Wakayama Medical University Hospital RECRUITING Wakayama Japan Details
Research Site NOT_YET_RECRUITING Busan South Korea Details
Research Site NOT_YET_RECRUITING Hwasun South Korea Details
Research Site NOT_YET_RECRUITING Seongnam South Korea Details
Research Site NOT_YET_RECRUITING Seoul South Korea Details
Research Site NOT_YET_RECRUITING Bangkok Thailand Details
Research Site NOT_YET_RECRUITING Chiang Mai Thailand Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field